This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusiononcoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP):
Intensify research on the major drivers of childhood cancers:
Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.